CDA and familial pancreatic carcinoma: Here, we performed a prospective clinical trial in gemcitabine-treated patients with resected pancreatic cancer which aimed at investigating the impact of CDA deficiency on the occurrence of toxicities and on pharmacokinetics, but also to better understand CDA genotype-phenotype relationships.